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Emerging research has identified that neuroimmune factors are produced by cells of
the central nervous system (CNS) and play critical roles as regulators of CNS function,
directors of neurodevelopment and responders to pathological processes. A wide range
of neuroimmune factors are produced by CNS cells, primarily the glial cells, but the role of
specific neuroimmune factors and their glial cell sources in CNS biology and pathology have
yet to be fully elucidated. We have used transgenic mice that express elevated levels of
a specific neuroimmune factor, the cytokine IL-6 or the chemokine CCL2, through genetic
modification of astrocyte expression to identify targets of astrocyte produced IL-6 or CCL2
at the protein level. We found that in non-transgenic mice constitutive expression of IL-6
and CCL2 occurs in the two CNS regions studied, the hippocampus and cerebellum, as
measured by ELISA. In the CCL2 transgenic mice elevated levels of CCL2 were evident in
the hippocampus and cerebellum, whereas in the IL-6 transgenic mice, elevated levels
of IL-6 were only evident in the cerebellum. Western blot analysis of the cellular and
synaptic proteins in the hippocampus and cerebellum of the transgenic mice showed that
the elevated levels of CCL2 or IL-6 resulted in alterations in the levels of specific proteins
and that these actions differed for the two neuroimmune factors and for the two brain
regions. These results are consistent with cell specific profiles of action for IL-6 and CCL2,
actions that may be an important aspect of their respective roles in CNS physiology and
pathophysiology.
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INTRODUCTION
Immune factors that play a critical role in the peripheral immune
system, such as cytokines and chemokines, are now known to
be produced within the CNS by cells of the CNS and to play
important roles in normal CNS functions as well as pathological
states (Gruol and Nelson, 1997; Glabinski and Ransohoff, 1999;
Bajetto et al., 2001; Banisadr et al., 2005; Deverman and Patterson,
2009; Spooren et al., 2011; Erta et al., 2012; Arisi, 2014). Immune
factors produced by CNS cells are referred to as neuroimmune
factors to distinguish their origin from immune factors that are
produced by cells of the peripheral immune system trafficketing
through the CNS. The primary source of neuroimmune factors
in the CNS is glial cells (astrocytes and microglia) (Kettenmann
et al., 2011; Smith et al., 2012; Jensen et al., 2013; Choi et al.,
2014). Depending on conditions, some neurons also produce
neuroimmune factors (Tsakiri et al., 2008; Wei et al., 2013).
Production of neuroimmune factors in the CNS is generally
low, but increases significantly during adverse conditions such
as injury and disease, when neuroimmune factors are thought
to play important protective and/or repair roles. However, if the
production of neuroimmune factors becomes dysregulated, the
elevated levels may promote pathological processes rather than
ameliorate the negative effects of adverse conditions.
CNS cells produce multiple neuroimmune factors, particularly
during adverse conditions. The complexity of this situation makes
it difficult to distinguish effects of individual neuroimmune fac-
tors and to identify target sites of action, information that is basic
to an understanding of physiological and pathological roles and
the development of new therapeutic strategies. Moreover, the cell
source of neuroimmune factors under physiological or patholog-
ical conditions can be questionable, as multiple CNS cell types
are capable of producing neuroimmune factors. To gain a clearer
understanding of the actions and potential roles of neuroimmune
factors in the CNS, we have focused on identifying the targets
of individual neuroimmune factors when the initial source is
CNS astrocytes. Astrocytes are closely associated with neurons
and synapses and are known to participate in processes that are
essential for normal CNS function, such as regulating synaptic
transmission (Halassa et al., 2007; Bernardinelli et al., 2014) and
neurodevelopment (Corty and Freeman, 2013). Neurons express
receptors for neuroimmune factors, consistent with a role for
these factors in astrocyte-neuron interactions. Moreover, astro-
cytes also express receptors for the same neuroimmune factors
that they produce, providing a mechanism for feedback control of
astrocyte function, and indirectly astrocyte regulation of neuronal
function.
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Two neuroimmune factors, the cytokine IL-6 and the
chemokine CCL2, are particularly relevant to a number of patho-
logical conditions. Elevated levels of these neuroimmune factors
in the CNS parenchyma or cerebrospinal fluid (CSF) have been
reported for a number of CNS disease states, and in partic-
ular, disease states associated with altered cognitive function.
For example, elevated levels of IL-6 occur in the CNS or CSF
of patients with clinical depression (Miller and O’Callaghan,
2005; Jones and Thomsen, 2013), active epilepsy (Billiau et al.,
2007), Alzheimer’s disease (Brosseron et al., 2014), HIV infection
(Gallo et al., 1989) and inflammatory neurological disorders
(Wullschleger et al., 2013). Similarly, elevated levels of CCL2
occur in the CNS or CSF in HIV infection (Cinque et al., 1998;
Kelder et al., 1998), multiple sclerosis (Conductier et al., 2010),
Alzheimer’s disease (Galimberti et al., 2006; Westin et al., 2012),
epilepsy (Wu et al., 2008), and psychiatric disorders (Stuart and
Baune, 2014). Although it is unknown whether IL-6 and CCL2
contribute to the cause and/or consequences of disease states
and symptoms, correlative evidence indicates a potential role
in the etiology of some disease states. For example, increased
levels of IL-6 were observed in the CNS of depressed patients
and correlated with the severity of symptoms (Lindqvist et al.,
2009). IL-6 levels were significantly higher in CSF of systemic
lupus erythematosus (SLE) patients that showed psychiatric man-
ifestations compared with SLE patients that did not show psy-
chiatric manifestations (Hirohata and Miyamoto, 1990; Hirohata
et al., 2009). IL-6 levels were significantly higher in the CSF of
patients with cerebrovascular disease with dementia compared
with patients with cerebrovascular disease without dementia
(Wada-Isoe et al., 2004). Elevated levels of IL-6 were found in the
CNS and CSF of autistic patients and correlated with increased
levels IL-6 expression by astrocytes (Vargas et al., 2005; Wei et al.,
2011). Similarly, increased levels of CCL2 were observed in the
CSF of HIV-infected individuals and correlated with the level
of viral load and severity of dementia (Kelder et al., 1998). In
older Alzheimer’s patients, increased levels of CCL2 in the CSF
correlated with cognitive deficits (Galimberti et al., 2006). CSF
levels of CCL2 increase significantly with the age of patients with
and without neuropsychiatric disease, suggesting that CCL2 plays
an important role in the detrimental effects of aging on the CNS
(Blasko et al., 2006). Experimental evidence also indicates a role
of IL-6 in aging, and in particular, the negative effects of aging on
cognitive function (Godbout and Johnson, 2004; Lekander et al.,
2011; Burton and Johnson, 2012).
In addition to a role in pathological conditions, expression of
IL-6 and CCL2 at low levels in the normal CNS suggest physiolog-
ical roles for these neuroimmune factors. Studies in experimental
animals support such a role for IL-6, but information on CCL2
is lacking. For example, the highest level of mRNA for both
IL-6 and IL-6 receptors in the CNS occurs in the hippocam-
pus, suggesting an important physiological role for IL-6 in the
hippocampus (Gadient and Otten, 1994a,b; Gruol and Nelson,
1997). Consistent with this possibility, recent studies showed that
astrocyte produced IL-6 provides homeostatic control of synaptic
function in hippocampal neuronal circuits involved in memory
and learning, essential cognitive functions that are disrupted in
Alzheimer’s disease and other neurologic disorders (Balschun
et al., 2004; Baier et al., 2009; del Rey et al., 2013). In these studies,
animals implanted with electrodes and subjected to a stimulation
paradigm that induced long-term potentiation (LTP) in the hip-
pocampus showed dramatically upregulated IL-6 gene expression
(Jankowsky et al., 2000; Balschun et al., 2004; del Rey et al., 2013).
LTP is a form of synaptic plasticity characterized by an enhance-
ment in the strength of synaptic transmission that is thought to
be a key cellular mechanism underlying memory and learning.
Studies using combined in situ hybridization and immunohisto-
chemistry identified astrocytes as the source of the elevated levels
of IL-6 in the LTP experiments (Jankowsky et al., 2000). Con-
sistent with these studies, IL-6 gene expression was shown to be
upregulated in behavioral experiments involving a hippocampal-
dependent learning task (i.e., a spatial learning task) (del Rey
et al., 2013). Behavioral studies of IL-6 deficient mice are also
consistent with a physiological role for IL-6 in hippocampal func-
tion. For example, IL-6 deficient mice showed impaired memory
in a behavioral test of hippocampal dependent memory (i.e., the
Morris water maze), a result consistent with a regulatory role for
IL-6 in memory management (Baier et al., 2009).
Studies involving exogenous application of IL-6 or CCL2
also support the idea that IL-6 and CCL2 can regulate neu-
ronal function and behavior, actions that could play a role in
the physiological or pathophysiological consequences of IL-6 or
CCL2 expression in the CNS. For example, our studies of cul-
tured hippocampus and cerebellum show that acute or chronic
exposure to IL-6 or CCL2 can alter the physiological properties
of neurons including neuronal excitability, synaptic transmission
and glutamate receptor function (e.g., Qiu et al., 1998; Nelson
et al., 2002, 2004; Gruol and Nelson, 2005; van Gassen et al.,
2005). Similarly, studies of hippocampal slices acutely isolated
from animals and studied in vitro showed that exogenous appli-
cation of IL-6 reduced LTP (Li et al., 1997; Tancredi et al.,
2000), while exogenous application of CCL2 to hippocampal
slices increased excitability and synaptic transmission (Zhou et al.,
2011). Exogenous application of CCL2 also increased neuronal
excitability in striatal slices from mice (Guyon et al., 2009). In
parallel studies, intranigral injections of CCL2 in mice increased
locomotor activity, a result consistent with the excitatory actions
of CCL2 in the slice studies (Guyon et al., 2009). Increasing the
CNS levels of IL-6 also altered the behavior of mice as assessed by
several different behavioral tests. For example, increasing levels of
IL-6 in the CNS of mice by the use of the adenovirus expression
system resulted in impaired cognitive ability and altered synaptic
function (Wei et al., 2012).
Thus, there is a growing body of knowledge that supports
physiological and/or pathological roles for IL-6 and CCL2 in
the CNS. However, the exact role of these neuroimmune factors
and mechanisms underlying their CNS actions are yet to be
elucidated. Our goal in the current study was to determine
if specific cellular and synaptic proteins are targets of IL-6 or
CCL2 action, effects that could contribute to the mechanisms
underlying the physiological or pathological actions of these
neuroimmune factors. For these studies, we took advantage of
two transgenic mouse models that express elevated levels of IL-6
or CCL2 in the CNS. In the transgenic mouse models, the elevated
levels of IL-6 or CCL2 were accomplished by gene manipulation
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of astrocyte expression. Astrocytes are the most abundant cell
type in the CNS (Heneka et al., 2010) and a primary producer
of IL-6 and CCL2 in the normal CNS and during pathological
conditions (Farina et al., 2007; Qin and Benveniste, 2012; Jensen
et al., 2013; Choi et al., 2014). Expression of IL-6 or CCL2 in the
astrocytes of the respective transgenic mice is under control of
the promoter for GFAP, an astrocyte specific structural protein.
Thus, the elevated production of these two neuroimmune factors
is likely to involve similar if not identical pathways, and, at least
initially, result in a similar spatial distribution of the secreted
peptide. Moreover, the restricted expression in astrocytes enables
identification of the initial source of the elevated levels of IL-6 or
CCL2 in the transgenic CNS.
Studies of mice from the IL-6 and CCL2 transgenic lines
indicate that the elevated astrocyte expression of the respective
neuroimmune factor has neurological effects, although most
effects were not prominent until later in the lifespan and differ
for the two transgenic lines. The IL-6 transgenic (tg) mice and
their non-transgenic (non-tg) littermates used in our study are
heterozygote, low expressor mice from the 167 line (Campbell
et al., 1993). Several studies have described the neurologic deficits
of these mice (Chiang et al., 1994; Heyser et al., 1997; Boztug
et al., 2002; Vallieres et al., 2002; Samland et al., 2003; Nelson
et al., 2012). The IL-6 tg mice progressively develop tremor and
ataxia by 6 months of age, indicative of cerebellar dysfunction,
and infrequently, seizures (Campbell et al., 1993). In tests of a
hippocampal-dependent behavior, avoidance learning, the IL-6 tg
mice show progressive deficits that were not prominent until 12
months of age. Thus, at 3 months of age there was no difference
in the ability of the IL-6 tg and non-tg mice to learn the avoidance
response, whereas at 6 months of age and older the IL-6 tg mice
progressively exhibited more errors in learning than the non-tg
mice (Heyser et al., 1997). Functional alterations at earlier ages (at
2 months of age) were also demonstrated by increased susceptibil-
ity of the IL-6 tg mice to kainic acid and NMDA induced seizures
(Samland et al., 2003) and enhanced synaptic transmission in
the IL-6 tg hippocampus studied in vitro (Nelson et al., 2012).
Interestingly, in transgenic mice that express elevated levels of
IL-6 through neuronal expression, including expression in hip-
pocampal pyramidal neurons and cerebellar Purkinje neurons,
astrogliosis but no neurological deficits were observed (Fattori
et al., 1995), suggesting that the source of IL-6 is an important
factor in the neuronal consequences of IL-6 actions in the CNS.
Characterization of the CCL2-tg mice is more limited than
for the IL-6 tg mice. However, in the heterozygote CCL2-tg mice
used in our studies, no overt CNS pathology or neurological
impairments were observed up to 7 months of age (Huang et al.,
2002, 2005). At older ages, neurological impairments such as
difficulty with righting reflex and limb weakness were observed
(Huang et al., 2005). Behavioral tests at 2–3 months of age showed
no significant difference between the CCL2-tg and CCL2 non-tg
animals in rotarod performance, a test of cerebellar function, or
in a behavior test of cued and contextual fear conditioning, which
involves hippocampal and amygdala function (Bray et al., 2013).
However, in vitro studies of hippocampal synaptic function at 2–3
months of age showed increased excitability in CA1 pyramidal
neurons in CCL2-tg hippocampus, indicative of neuroadaptive
changes due to the enhanced astrocyte expression of CCL2 (Bray
et al., 2013).
IL-6 and CCL2 produce their biological effects by acting at spe-
cific membrane receptors. The IL-6 receptor is a transmembrane
receptor that lacks a signal transduction element. Instead, IL-6
receptors utilize a common transmembrane signaling receptor
referred to as gp130 (glycoprotein 130). When activated by IL-
6, the IL-6 receptor associates with gp130 and induces dimer-
ization with a second gp130 (Taga and Kishimoto, 1997). The
gp130/gp130 homodimer can then activate JAK, STAT3, and/or
MAPK signaling cascades, which leads to gene expression and
other downstream actions. gp130 is widely distributed through-
out the CNS, but IL-6 receptor distribution is more restricted.
IL-6 can also produce biological effects by trans-signaling, which
results from shedding of the membrane receptor to form a soluble
receptor or alternative splicing of IL-6 receptor mRNA (Rose-
John et al., 2006). The soluble receptor after binding IL-6 can
interact with gp130 in IL-6 receptor expressing cells and in
cells that normally do not express IL-6 receptor but do express
gp130. Studies suggest that trans-signaling plays a central role in
pathological actions of IL-6 in the CNS (Rose-John et al., 2006;
Burton et al., 2011; Campbell et al., 2014). In contrast to IL-6,
receptors for chemokines including CCL2 are G-protein coupled
receptors (GPCRs) linked to Gi/Go. A variety of signal trans-
duction pathways are activated by chemokine receptors including
MAPK. These signal transduction pathways can ultimately lead to
altered gene expression and downstream changes in protein levels.
Therefore, modulation of protein levels could be one mechanism
through which IL-6 and CCL2 participate in homeostatic control
of neuronal and glial function, engage in protection and/or repair,
and/or take part in pathological processes.
To identify targets (direct or indirect) of astrocyte produced
IL-6 and CCL2 that are involved in the CNS actions of these
neuroimmune factors, we compared protein levels in the hip-
pocampus and cerebellum of IL-6 tg and CCL2-tg mice and their
non-tg littermates. Both CNS regions play key roles in behavior.
The hippocampus plays a key role in memory and learning, while
the cerebellum plays a key role in coordinated movement. Results
show that the levels of specific cellular and synaptic proteins are
altered by elevated astrocyte expression of IL-6 and/or CCL2 and
that these actions differed for the two neuroimmune factors in
an age and CNS region dependent manner. These results are
consistent with cell specific profiles of action for IL-6 and CCL2,
actions that may be an important aspect of their respective roles
in CNS physiology and pathophysiology.
MATERIALS AND METHODS
ANIMALS
All animal procedures were performed in accordance with the
Scripps Research Institute and the National Institutes of Health
Guideline for the Care and Use of Laboratory Animals. Animal
facilities and experimental protocols were in accordance with the
Association for the Assessment and Accreditation of Laboratory
Animal Care. Heterozygote IL-6 or CCL2 (previously known as
monocyte chemoattractant protein-1 or MCP-1) transgenic mice
and their non-transgenic littermates (as controls) were used for
all studies. The IL-6 line was obtained from Dr. Ian Campbell
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of the University of Sydney and the CCL2 line was obtained
from Dr. Richard Ransohoff of the Cleveland Clinic Foundation.
Methods for the generation of the transgenic lines were previously
published. Briefly, for the IL-6 line, full-length murine IL-6 cDNA
was modified and inserted into the glial fibrillary acidic protein
(GFAP) gene. The hybrid (transgene) DNA was subsequently
microinjected into fertilized eggs of (C57BL/6J × SJL) F1 hybrid
mice (Campbell et al., 1993). Transgene expression in astrocytes
was documented by in situ hybridization studies and expression
of the lacZ reporter gene as assessed by immunohistochemical
detection of β-gal (Campbell et al., 1993; Vallieres et al., 2002). For
the CCL2 line, the murine CCL2 gene was placed under control
of the huGFAP promoter and a purified GFAP-CCL2 fusion gene
fragment was injected into fertilized eggs of SWXJ (H-21q,s) mice
(Huang et al., 2002). For both lines, transgenic offspring were
identified by analysis of tail DNA using standard protocols. Cut
tail tips from individual animals were obtained at weaning (21–
28 days postnatal). Tail DNA was extracted using the Mouse Tail
Quick Extraction Kit (Pioneer Inc., San Diego CA). Mice positive
for the IL-6 or CCL2 transgene were identified by PCR. Samples
were prepared for PCR using the HotStart Taq Master Mix with
Loading Dye (Pioneer). Both lines are congenic and have been
maintained for several years by breeding heterozygous transgenic
mice with wildtype C57BL/6J mice.
PROTEIN ASSAYS
Protein samples for ELISA or Western blot assays were prepared
from hippocampus and cerebellum of transgenic and non-
transgenic mice using standard protocols. To obtain the tissue,
mice were anesthetized with isoflurane and decapitated. The
brains were rapidly removed and immersed in chilled artificial
cerebral spinal fluid (ACSF). The ACSF composition was 130.0
mM NaCl, 3.5 mM KCl, 1.25 mM NaH2PO4, 24.0 mM NaHCO3,
0.2 mM CaCl2, 5.0 mM MgSO4, and 10.0 mM glucose (all
chemicals from Sigma-Aldrich, St. Louis, MO). The ACSF was
maintained on ice and was bubbled continuously with 95%
O2/5% CO2 to provide oxygen and to stabilize pH at 7.2–7.4. The
hippocampus and cerebellum were dissected from the brain, snap
frozen on dry ice and stored at −80◦C until use. In some studies,
instead of immediately freezing the hippocampus, hippocampal
slices were prepared using a protocol previously described
(Nelson et al., 2011). Briefly, after cooling the brain in ACSF,
the left and right hippocampi were removed from the brain and
cut into 400 µm slices using a McIlwain tissue chopper (Mickle
Laboratory Engineering Co. Ltd., Surrey, UK). Approximately
six slices were obtained from each hippocampus. The slices were
placed in two gas-fluid interface chambers maintained at ∼33◦C
and were continuously superfused with oxygenated ACSF at rate
of 0.55 ml/min to retain viability. After 2 h incubation, slices were
pooled according to chamber, snap frozen and stored at−80◦C.
Proteins were extracted from all tissue samples by sonication
in cold lysis buffer containing 50 mM Tris-HCL, pH 7.5,
150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.5% NP-
40, a Complete Protease Inhibitor Cocktail Tablet (Roche
Diagnostics, Mannheim, Germany), and a cocktail of phosphatase
inhibitors (Na+ pyrophosphate, β-glycerophosphate, NaF, Na+
orthovanadate; all from Sigma-Aldrich). The samples were
incubated on ice for 30 min, centrifuged at 13,860 g for 30 min at
4◦C, and the supernatants were collected. Protein concentration
in the supernatants was determined using the Bio-Rad Protein
Assay Kit (Bio-Rad, Hercules, CA). Aliquots were stored at
−80◦C.
IL-6 and/or CCL2 levels in hippocampal and cerebellar
protein samples were determined by ELISA using the Mouse IL-6
ELISA Ready-SET-Go! Kit or the Mouse CCL2 ELISA Ready-
SET-Go! Kit, respectively (eBioscience, Inc., San Diego, CA)
following manufacturer’s instructions. Levels of other proteins
were determined by Western blot following previously published
protocols (Nelson et al., 2012). Briefly, equal amounts of
hippocampal or cerebellar protein samples were subjected to SDS-
PAGE using 4–12% Novex NuPAGE Bis-Tris gels (Invitrogen Life
Technologies, Grand Island, NY). Transgenic and non-transgenic
protein samples were run on the same gel. Samples were run in
duplicate. Proteins were transferred to Immobilon-P membranes
(Millipore, Billerica, MA) and uniform transfer assessed by Pon-
ceau S staining (Pierce, Rockford, IL). Membranes were washed
and blocked in a 5% casein solution (Pierce). The membranes
were incubated in primary antibody overnight (4◦C), washed,
and then incubated (room temperature) in secondary antibody
coupled to horseradish peroxidase (HRP). Protein bands were
visualized by chemiluminescence and quantified by densitometry
measurements using NIH Image software.1 Membranes were
stripped and reprobed for β-actin. To adjust for possible loading
errors, the density of each band was normalized to the density
of the band for β-actin in the same lane. Normalized data from
transgenic mice were then normalized to the average normalized
value for non-transgenic mice run on the same gel. In some
studies to enable comparisons, hippocampal and cerebellar
samples were run on the same ELISA and/or Western blot. Also,
in some studies CCL2 and IL-6 samples were run on the same
ELISA and/or Western blot. Data were combined according to
mouse line, genotype and age of the animal and reported as mean
± SEM.
The following antibodies were used for Western blot studies:
a monoclonal antibody to β-actin (#AC-15, 1:5000; Sigma, St.
Louis, Missouri); a monoclonal antibody to GFAP (#MAB360;
1:10,000; Millipore); a monoclonal antibody raised against neu-
ron specific enolase (#MAB314; 1:5000; Millipore); a mouse mon-
oclonal antibody to glutamine synthetase (Glu syn) raised against
a recombinant fragment corresponding to amino acids 274–
374 of human glutamine synthetase (ab64613; 1:1000; abcam,
Cambridge, MA); a purified rabbit polyclonal antibody raised
against a peptide mapping at the carboxy terminus of C/EBP
beta (C-19; 1:500; Santa Cruz Biotechnology, Santa Cruz, CA);
a rabbit polyclonal antibody raised against a synthetic peptide
to the C-terminus of rat GAD 65/67 (#AB1511; 1:1000; Mil-
lipore); a purified rabbit antibody to synapsin 1 (#51-5200;
1:5,000; Invitrogen; Syn 1); a purified rabbit polyclonal antibody
raised against a synthetic peptide of the rat GluA1 subunit of
the AMPA receptor conjugated to keyhole limpet hemocyanin
(KLH; a protein carrier) with a cysteine added (#07-660; 1:500;
Millipore); a purified goat polyclonal antibody raised against a
1http://rsb.info.nih.gov/nih-image/
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peptide corresponding to an amino acid mapping the C-terminus
of the human GluN1 subunit of the NMDA receptor (sc-1467;
1:500; Santa Cruz Biotechnology); a rabbit polyclonal antibody
raised against p44/p42 MAPK (#61-7400; 1:5000, Zymed, Carls-
bad, CA, USA); a purified rabbit polyclonal antibody raised
against a synthetic phospho-peptide (KLH-coupled) correspond-
ing to residues around Thr202/Tyr204 of human p44/p42 MAPK
(#9101; 1:500; Cell Signaling Technologies, Danvers, MA; pp44/42
MAPK); a purified rabbit polyclonal antibody raised against a
synthetic peptide (KLH-coupled) corresponding to the sequence
of mouse STAT3 (AB#9132; 1:1000; Cell Signaling Technologies),
a purified rabbit polyclonal antibody raised against a synthetic
phospho-peptide (KLH-coupled) corresponding to the residues
surrounding Tyr705 of mouse STAT3 (AB#9131; 1:1000; Cell
Signaling Technologies).
STATISTICAL ANALYSES
Statistical analyses of differences were performed using the
unpaired t-test or ANOVA. Statistical significance was set at p
< 0.05. For most studies, statistical comparisons were made
between transgenic (IL-6 tg or CCL2-tg) vs. non-transgenic (IL-6
non-tg or CCL2 non-tg) values for hippocampus or cerebellum
within the same age group and mouse line. For the IL-6 line
results were obtained from: (a) mice 1–2 months of age: 25 IL-6
tg and 31 non-tg hippocampi (52 Western blots) and 9 IL-6 tg
and 12 non-tg cerebella (73 Western blots); (b) mice 3–5 months
of age: 42 IL-6 tg and 41 non-tg hippocampi (69 Western blots)
and 9 IL-6 tg and 10 non-tg cerebella (17 Western blots); (c)
mice 12 months of age: 10 IL-6 tg and 9 non-tg hippocampi (41
Western blots) and 11 IL-6 tg and 8 non-tg cerebella (21 Western
blots). For the CCL2 line results were obtained from: (a) mice
1–2 months of age: 11 CCL2-tg and 11 non-tg hippocampi (34
Western blots) and 8 CCL2-tg and 9 non-tg cerebella (7 Western
blots); (b) mice 3–5 months of age: 30 CCL2-tg and 23 non-tg
hippocampi (56 Western blots) and 25 CCL2-tg and 26 non-tg
cerebella (15 Western blots); and (c) mice 7–9 months of age: 26
CCL2-tg and 26 non-tg hippocampi (45 Western blots).
RESULTS
IL-6 AND CCL2 EXPRESSION
Levels of IL-6 and CCL2 in hippocampus and cerebellum of trans-
genic and non-transgenic mice at different ages were determined
by ELISA. Results are shown in Figure 1. For the IL-6 line, low
levels of IL-6 were observed in the hippocampus with no apparent
genotypic difference (Figure 1A). IL-6 levels in the cerebellum
were higher than in the hippocampus and a significant genotypic
difference was observed (IL-6 tg > non-tg; Figure 1A). No promi-
nent age-dependent differences were observed for levels of IL-6
in IL-6 tg and non-tg hippocampus and cerebellum. In contrast,
levels of CCL2 were prominent in the CCL2-tg hippocampus and
higher in the hippocampus than in the cerebellum. CCL2 levels
showed a significant genotypic difference (CCL2-tg > non-tg)
in both CNS regions (Figure 1B). No prominent age-dependent
differences were observed for levels of CCL2 in CCL2-tg and non-
tg hippocampus. CCL2 levels were also measured in the IL-6 tg
and non-tg hippocampus and cerebellum and were comparable to
that observed in the CCL2 non-tg hippocampus and cerebellum
(Figure 1C). Similarly, IL-6 levels were measured in the CCL2-tg
and non-tg hippocampus and cerebellum and were comparable
to that observed in the IL-6 non-tg hippocampus and cerebellum
(data not shown).
To determine if astrocytes constitutively secrete IL-6 or
CCL2, an in vitro experimental protocol was used. In these
studies, hippocampal slices were prepared from transgenic and
non-transgenic mice and IL-6 or CCL2 levels were measured in
the tissue after an in vitro incubation period. The rationale for
these studies is that if the astrocytes in the CCL2-tg or IL-6 tg
hippocampus constitutively secrete CCL2 or IL-6, respectively,
tissue levels would decline during the incubation period,
provided that the rate of synthesis did not match release. To
identify such a change, tissue levels in the slices after incubation
were compared to levels in hippocampal tissue that was directly
snap frozen after removal from the animal. The protocol for the
preparation and maintenance of the slices followed a standard
protocol used for neurophysiological studies of hippocampal
slices in vitro (e.g., Nelson et al., 2012). The slices were incubated
for 2 h under physiological conditions with constant superfusion
of oxygenated ACSF to maintain viability and remove secreted
protein from the slices. The slices were then snap frozen for
later protein assay. Results from ELISA measurements are shown
in Figures 1D,E. Hippocampal samples prepared from tissue
directly snap frozen after removal from the animal were measured
in the same ELISAs. Levels of IL-6 in slices were generally higher
than in the animal samples (Figure 1D), whereas the opposite
was the case for CCL2 (Figure 1E). The most dramatic effect
was a prominent reduction in the level of CCL2 in CCL2-tg
hippocampal slices compared with hippocampal samples directly
obtained from CCL2-tg animals. This result is consistent with
constitutive astrocyte secretion of CCL2 (Figure 1E). Although
constitutive secretion of IL-6 from astrocytes may have occurred,
the higher levels of IL-6 in the hippocampal slices confounded
assessment of secretion. The higher levels of IL-6 in the slices may
have resulted from increased production, perhaps induced by
the experimental manipulations. Alternatively, the higher levels
could reflect reduced secretion, perhaps because IL-6 secretion
from astrocytes requires a specific trigger.
Taken together, results from these studies show prominent
differences in the levels of astrocyte produced IL-6 or CCL2
in the respective transgenic mice both within and across CNS
regions. They also show that in vitro incubation differentially
alters the levels of IL-6 and CCL2 in hippocampal tissue. These
differences indicate that astrocyte production and/or trafficking
varies for these two neuroimmune factors. In addition, these
results show that increased expression of IL-6 does not trigger
increased expression of CCL2 in the two CNS regions studied.
HOUSEKEEPING PROTEINS
To assess global effects of upregulated astrocyte expression of
IL-6 or CCL2 in the hippocampus and cerebellum, several
housekeeping proteins were measured by Western blot in tis-
sue obtained from transgenic and non-transgenic mice at dif-
ferent ages. These proteins included β-actin, a cytosketal pro-
tein expressed in all cells, GFAP, an astrocyte specific cytosketal
protein, glutamine synthetase, a protein important in astrocyte
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FIGURE 1 | Levels of IL-6 and CCL2 protein in transgenic and
non-transgenic hippocampus and cerebellum determined by ELISA.
(A) IL-6 levels (mean ± SEM) in the hippocampus and cerebellum of IL-6 tg
and non-tg mice at different ages. (B) CCL2 levels (mean ± SEM) in
CCL2-tg and non-tg hippocampus and cerebellum at different ages. (C)
CCL2 levels (mean ± SEM) in CCL2 non-tg hippocampus and cerebellum
and IL-6 tg and non-tg hippocampus and cerebellum at 3–5 months of age.
Numbers in bars are the number animals measured. * = statistically
significant difference (p < 0.05, unpairedt-test) from non-tg of the same
treatment group. (D,E) IL-6 (D) and CCL2 (E) levels in hippocampal samples
with in vitro incubation (slices) or without (animals). For slices, numbers in
bars are the number of samples measured (two samples/animal; left and
right hippocampus). For animals, numbers in bars are the numbers of
animals measured. * = statistically significant difference (p < 0.05,
unpaired t-test) between slices and animal samples of the same
genotype.
trafficking of glutamate, and neuron specific enolase, a specific
neuronal protein. Results are shown in Figures 2, 3. In the IL-
6 line, a significant genotypic difference (IL-6 tg > non-tg) was
observed for GFAP levels in the hippocampus and cerebellum
at all ages studied (Figure 2A). There was no significant geno-
typic difference in the levels of β-actin, glutamine synthetase
and enolase in hippocampus at all ages studied. However, age-
dependent genotypic differences were observed in the cerebellum.
A prominent increase in the level of glutamine synthetase was
observed at 1–2 months of age in the IL-6 tg cerebellum with a
smaller increase at 3–5 months of age. A significant decrease in
the level of enolase was also observed in the IL-6 tg cerebellum at
1–2 months of age. In addition, β-actin levels showed an increase
in the IL-6 tg cerebellum at 3–5 months of age. No genotypic
differences were observed in the IL-6 cerebellum at other ages
studied. In contrast, in the CCL2 line, there were no genotypic
differences in the levels of GFAP, β-actin, glutamine synthetase
and enolase in the hippocampus or cerebellum at the ages studied
(Figure 3A).
Taken together, these results show that increased expression
of IL-6 in the IL-6 tg hippocampus and cerebellum, although
not detected by ELISA in the hippocampus, has a pronounced
effect on the expression of some hippocampal and cerebellar
housekeeping proteins such as GFAP. Increased expression of
CCL2, which can be detected by ELISA, has no apparent effect on
levels of the same proteins. In addition, the absence of increased
levels of GFAP in the CCL2-tg hippocampus and cerebellum
indicates that CCL2 does not induce upregulated levels of IL-6
in these CNS regions of the CCL2-tg mice.
SIGNAL TRANSDUCTION PROTEINS
The level of signal transduction proteins p42/44 MAPK, STAT3
and C/EBPβ were also measured by Western blot in the hip-
pocampus and cerebellum of the transgenic and non-transgenic
mice (Figures 2B, 3B). All three signal transduction proteins
are known to be important regulators of normal neuronal and
glial development and function (Sterneck and Johnson, 1998;
Taubenfeld et al., 2001; Thomas and Huganir, 2004; Paquin et al.,
2005; Ejarque-Ortiz et al., 2007; Dziennis and Alkayed, 2008;
Kfoury and Kapatos, 2009; Cheng et al., 2013; Nicolas et al., 2013).
For example, in the hippocampus, p42/44 MAPK and STAT3
play central roles in synaptic plasticity involved in memory and
learning (Sweatt, 2001; Nicolas et al., 2012). Importantly, STAT3
and p42/44 MAPK are key players in IL-6 signal transduction and
p42/44 MAPK is also involved in CCL2 signal transduction.
No significant genotypic differences in the levels of p42/44
MAPK were observed in the IL-6 hippocampus or cerebellum at
the ages studied (Figure 2B). In contrast, a significant increase
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FIGURE 2 | Protein levels in hippocampus and cerebellum of IL-6 tg
and non-tg mice at different ages determined by Western blot. (A)
Mean (±SEM) values for levels of housekeeping proteins. (B) Mean
(±SEM) values for levels of signal transduction proteins. (C) Mean
(±SEM) values for levels of synaptic proteins. Representative Western
blots are shown above the respective bar. Top blot is the protein
indicated for the graph; bottom blot is β actin in the same lane.
Numbers in bars are the number of animals measured. * =
statistically significant difference between IL-6 tg and non-tg for the
age group.
in STAT3 levels was observed in the IL-6 tg hippocampus and
cerebellum at all ages studied (Figure 2B). C/EBPβ levels were
prominently increased in the IL-6 tg cerebellum at 1–2 months
of age, but not at other ages or in the IL-6 tg hippocampus
(Figure 2B). No genotypic differences were observed in the hip-
pocampus and cerebellum of the CCL2 line for p42/44 MAPK,
STAT3 or C/EBPβ (Figure 3B).
Levels of the active form (i.e., phosphorylated form) of STAT3
(pSTAT3) were also examined in hippocampus and cerebellum
from IL-6 tg and non-tg mice (3–5 months of age). Results
showed that pSTAT3 levels were prominently increased in the
IL-6 tg hippocampus (normalized values—tg/non-tg: IL-6 tg =
4.0 ± 0.9, n = 7; IL-6 non-tg = 1.0 ± 0.2, n = 7) and cerebellum
(normalized values—tg/non-tg: IL-6 tg = 297 ± 102, n = 9;
IL-6 non-tg = 1.0 ± 0.2, n = 7). Levels of the active form
(i.e., phosphorylated form) of p42/44 MAPK (pp42/44 MAPK)
were examined in hippocampus from IL-6 tg and non-tg mice
(3–5 months of age) and in hippocampus from CCL2-tg and
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FIGURE 3 | Protein levels in hippocampus and cerebellum of
CCL2-tg and non-tg mice at different ages determined by Western
blot. (A) Mean (±SEM) values for levels of housekeeping proteins. (B)
Mean (±SEM) values for levels of signal transduction proteins. (C)
Mean (±SEM) values for levels of synaptic proteins. Representative
Western blots are shown above the respective bar. Top blot is the
protein indicated for the graph; bottom blot is β actin in the same
lane. Numbers in bars are the number of animals measured. * =
statistically significant difference between CCL2-tg and non-tg for the
age group.
non-tg mice (3–9 months of age). The IL-6 tg hippocampus
showed a 30% increase in pp42/44 MAPK relative to the non-tg
hippocampus (normalized values—tg/non-tg: pp42 MAPK, IL-6
tg = 1.3 ± 0.1, n = 9; IL-6 non-tg = 1.0 ± 0.1, n = 8; pp44
MAPK, IL-6 tg = 1.3 ± 0.1, n = 9; IL-6 non-tg = 1.0 ± 0.1,
n = 8). The CCL2-tg hippocampus showed a 30% decrease
in pp44 MAPK but no change in pp42 MAPK relative to the
non-tg hippocampus (normalized values—tg/non-tg: pp42
MAPK, CCL2-tg = 1.0 ± 0.1, n = 17; CCL2 non-tg = 1.0 ± 0.05,
n = 19; pp44 MAPK, CCL2-tg = 0.7 ± 0.1, n = 10; CCL2
non-tg = 1.0± 0.1, n = 13).
SYNAPTIC PROTEINS
Our previous studies showed that upregulated astrocyte expres-
sion of IL-6 or CCL2 in the respective transgenic mice produced
neuroadaptive changes that altered synaptic function (Nelson
et al., 2011, 2012; Bray et al., 2013). To determine if neuroad-
aptive changes occurred at the level of synaptic protein expres-
sion, we examined pre- and post-synaptic proteins by Western
blot in hippocampus and cerebellum from transgenic and non-
transgenic mice. Two presynaptic proteins were examined, Syn
1, a synaptic vesicle protein involved in transmitter release, and
GAD65/67, the synthetic enzyme for the inhibitory transmitter
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GABA. Two postsynaptic proteins were also examined, GluA1,
a subunit of the AMPA receptor, and GluN1, a subunit of the
NMDA receptor. Both glutamate receptors, GluA1 and GluN1,
are important mediators of excitatory synaptic transmission in
hippocampal and cerebellar circuits.
Results show both age and region-dependent genotypic
differences, the most pronounced effects occurring in the IL-6
tg cerebellum. In the IL-6 line, there was a small (∼7%) but
significant decrease in GAD65/67 in the IL-6 tg hippocampus
at 3–5 months of age and a significant decrease in the levels
of Syn 1 and GluN1 at 12 months of age (Figure 2C). Levels
of Syn 1, GAD65/67, GluA1 and GluN1 were all significantly
reduced in the IL-6 tg cerebellum at all ages studied. In the CCL2-
tg hippocampus, levels of Syn 1 and GluN1 were significantly
increased at 3–5 months of age, whereas the level of GAD 65/67
was significantly decreased at 7–9 months of age (Figure 3C).
There was no significant genotypic difference in levels of Syn 1,
GAD65/67, GluA1 and GluN1 in the CCL2-tg cerebellum at all
ages studied (Figure 3C).
DISCUSSION
In the current study we measured the relative levels of cellu-
lar and synaptic proteins expressed in the hippocampus and
cerebellum of transgenic mice that are genetically modified to
produce elevated levels of IL-6 or CCL2 in CNS astrocytes. The
goal of these studies was to identify CNS targets of the astrocyte
produced IL-6 or CCL2, as evidenced by a change in the level of
protein expression. Measurements were made at several ages in
the lifespan of the animals, to reveal changes that could reflect
developmental sensitivity and/or duration of exposure. Results
show several changes in the level of neuronal and glial proteins in
the hippocampus and cerebellum of the IL-6 tg mice but relatively
few in the CCL2-tg mice (Table 1). Some changes were age and/or
region specific. The ability of elevated levels of IL-6 or CCL2 to
produce such changes could play a role in neurological, psychi-
atric or other disorders that show persistently elevated levels of
IL-6 or CCL2 in the CNS. Moreover, IL-6 or CCL2 regulation of
these targets could play a role in the normal physiological function
of these CNS regions.
ELISA studies confirmed the presence of elevated levels of
IL-6 and CCL2 in the hippocampus and/or cerebellum of the
respective transgenic mice at all ages studied. Elevated levels were
observed at the youngest age studied, 1–2 months of age, with
no apparent age-dependent difference in the expression pattern
at older ages. Animals at 1–2 months of age are considered to
be adolescent/young adults, whereas the older ages (3–5 and
7–12) studied are considered to be adult ages. Astrocytes normally
start to produce GFAP about 1 week postnatal with expression
continuing throughout the lifetime of the animal. CNS expression
of mRNA for IL-6 and CCL2 also begins during the postnatal
period in normal animals (Gadient and Otten, 1994a; Pousset,
1994). CNS expression of IL-6 mRNA in the IL-6 transgenic mice
was evident at 1 week postnatal and reached a maximum at 3
months of age (Chiang et al., 1994). GFAP mRNA expression,
which is regulated by IL-6, and GFAP protein were also evident
at 1 week postnatal but an increased level of GFAP in the IL-
6 tg CNS was not prominent until about 1 month postnatal
(Chiang et al., 1994). These results suggest that the consequences
of elevated expression of IL-6 in the CNS are not prominent until
about 1 month of age. CCL2 expression in CCL2-tg mice has not
been studied at early ages but it is likely that the time course of
expression is similar to that for IL-6, because the elevated levels of
expression for both IL-6 and CCL2 is linked to GFAP expression
in astrocytes (Brenner et al., 1994).
Elevated levels of IL-6 were not observed in the CCL2-tg
hippocampus or cerebellum, indicating that elevated levels of
CCL2 did not induce production of IL-6 in these CNS regions.
Similarly, elevated levels of CCL2 were not observed in the IL-6
tg hippocampus and cerebellum, suggesting that elevated levels
of IL-6 did not induce production of CCL2. These results are
consistent with in vitro studies of cultured astrocytes involving
exogenous application of IL-6 or CCL2 (Oh et al., 1999; Semple
et al., 2010) and suggest that glial activation was not prominent
in the transgenic mice. In both the transgenic and non-transgenic
hippocampus and cerebellum, levels of CCL2 were considerably
higher than levels of IL-6. This difference was also observed in
CSF samples from human control subjects, the most common
site for measurement of neuroimmune factors in humans. For
example, IL-6 levels were reported to be ∼1 pg/ml in the human
CSF (Lindqvist et al., 2009) compared with∼840 pg/ml for CCL2
in human CSF (Janelidze et al., 2013).
Elevated levels of CCL2 were observed in the hippocampus and
cerebellum of the CCL2-tg mice, but elevated levels of IL-6 were
only observed in the cerebellum in the IL-6 tg mice. Moreover,
IL-6 levels were higher in the cerebellum than in the hippocampus
of the IL-6 tg mice, whereas in the CCL2 tg mice, CCL2 levels were
higher in the hippocampus than the cerebellum. These regional
difference may relate to differences in the production of these two
neuroimmune factors by the Bergman glia, which are present in
the cerebellum but not in the hippocampus. The Bergman glia
express the highest level of IL-6 transgene in the IL-6 transgenic
CNS (Campbell et al., 1993). The high levels of IL-6 in the IL-6 tg
cerebellum may contribute to the damage and cell loss observed
in this brain region at older ages, and consequently the ataxia
characteristic of the older IL-6 tg mice (Campbell et al., 1993).
A neurotoxic effect of high concentrations of IL-6 is consistent
with our previous studies in a culture model, which showed
that neurotoxicity was produced when cultured cerebellar granule
neurons were exposed chronically to high concentrations of IL-6
in the culture media (e.g., 5–10 ng/ml) (Conroy et al., 2004).
Previous studies of rat brain showed higher levels IL-6 mRNA
in the hippocampus than in the cerebellum (Gadient and Otten,
1994a), whereas our ELISA studies of non-tg mice showed higher
levels of IL-6 protein in the cerebellum than in the hippocampus.
Thus, there appears to be a mismatch between mRNA and protein
levels. Because both cerebellar and hippocampal samples were
run on the same ELISA, it is unlikely that technical difficulties
account for this difference. Assuming that this apparent mismatch
is not due to an across species comparison, it is likely that brain
region specific post-translational events (e.g., post-translational
regulation) are responsible for the mismatch between mRNA and
protein levels observed in our studies, as has been shown for other
proteins in other systems (Shebl et al., 2010; Khositseth et al.,
2011; Vogel and Marcotte, 2012).
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Table 1 | Changes in protein expression in hippocampus and cerebellum of IL-6 and CCL2 transgenic mice.
IL-6 CCL2
Hippocampus Cerebellum Hippocampus Cerebellum
Protein 1–2 months 3–5 months 12 months 1–2 months 3–5 months 12 months 1–2 months 3–5 months 7–9 months 1–2 months 3–5 months 7–9 months
β-actin none none none none N none none none none none none nd
GFAP N N N N N N none none none none none nd
Glu syn none none none N N none none none none none none nd
Enolase none none none H none none none none none none none nd
p42 MAPK none none none none none none none none none none none nd
p44 MAPK none none none none none none none none none none none nd
STAT3 N N N N N N none nd none none none nd
C/EBPβ none none none N none none none nd none none none nd
Synapsin 1 none none H H H H none none none none none nd
GAD65/67 none H none H H H none none H none none nd
GluA1 none none none H H nd none none none none none nd
GluN1 none none H H H nd none N none none none nd
* for each group, tg is compared to non-tg; N = tg > non-tg; H = tg < non-tg; none = no significant difference between tg and non-tg; nd = not determined.
Although elevated levels of IL-6 were not observed in the
IL-6 tg hippocampus, evidence for increased expression of IL-6
was provided by our Western blot results showing elevated levels
GFAP, STAT3 and pSTAT3 in both hippocampus and cerebellum.
GFAP levels are known to be regulated by IL-6 through a signal
transduction pathway involving STAT3 (Heinrich et al., 1998;
Herrmann et al., 2008; Shu et al., 2011). Therefore, the increased
levels of GFAP, STAT3 and pSTAT3 provide evidence of increased
production of IL-6. The differences in the ability to detect elevated
levels of IL-6 vs. CCL2 in the respective transgenic tissue suggests
that astrocyte trafficking differs for IL-6 and CCL2 and imply
that IL-6 is likely to be released after production, whereas CCL2
can be released and/or stored. Studies of astrocytes cultured from
the CNS of IL-6 tg or CCL2-tg mice demonstrated the ability of
astrocytes to secrete IL-6 (Campbell et al., 1993) or CCL2 (Huang
et al., 2002), respectively. For example, IL-6 bioactivity in the
supernatant of cultured astrocytes obtained from the CNS of IL-
6 tg mice was approximately 150 pg/ml compared with 5 pg/ml
for IL-6 non-tg astrocytes (Campbell et al., 1993). CCL2 levels in
the supernatant of cultured astrocytes obtained from the CNS of
CCL2-tg mice was approximately 3500 pg/ml compared with 1
pg/ml for astrocytes from the CCL2 non-tg mice (Huang et al.,
2002).
Differences in the levels of cellular and synaptic protein mea-
sured by Western blot between the IL-6 tg and IL-6 non-tg
mice were observed for both the hippocampus and cerebellum.
However, the cerebellum showed more prominent effects of
IL-6 than the hippocampus, presumably due to the higher level of
expression of IL-6 in the cerebellum. Differences in cell types that
comprise the two regions could also be a contributing factor. The
proteins most affected by the elevated levels of IL-6 in both CNS
regions were GFAP, STAT3 and pSTAT3, which were all increased.
GFAP is restricted to astrocytes, whereas STAT3 is expressed by
both neurons and glia, as are IL-6 receptors (Schöbitz et al.,
1992; Planas et al., 1997; Nelson et al., 1999; Murata et al., 2000).
Because our studies used whole hippocampus and cerebellum, we
were unable to identify the cell types or subcellular compartments
that showed the increased STAT3 and pSTAT3 levels in these CNS
regions. In previous studies of the IL-6 tg cerebellum, pSTAT3 was
detected primarily in the nucleus of glial cells (Sanz et al., 2008),
suggesting that glial cells are the primary cell type responding to
the chronic expression of IL-6 in the IL-6 tg cerebellum. However,
the primary site of neuronal effects may be at non-nuclear sites.
Both STAT3 and pSTAT3 have been shown to be localized to
synaptic sites in the hippocampus and cortex (Murata et al.,
2000) and, independent of nuclear localization, to play a role
in long-term depression, a form of synaptic plasticity essential
for normal CNS function (Nicolas et al., 2012). LTP, another
form of synaptic plasticity, has been shown to be regulated by
IL-6 in the hippocampus and to involve glial release of the IL-
6, which presumably acts at neuronal IL-6 receptors (Li et al.,
1997; Jankowsky et al., 2000; Tancredi et al., 2000; Balschun
et al., 2004). IL-6 signaling through IL-6 receptors involving
both STAT3 and/or p42/44 MAPK has been demonstrated in
neuronal cells (Schumann et al., 1999; Park et al., 2012; Fang
et al., 2013). Thus, the elevated levels of STAT3 and/or pSTAT3
could occur primarily at synaptic or other subcellular sites in
neurons in the IL-6 tg mice, a possibility that will require further
investigation.
In addition to GFAP, another glial protein was increased in
the IL-6 tg cerebellum, glutamine synthetase. This protein was
not elevated in the IL-6 tg hippocampus and was only promi-
nently elevated at 1–2 months of age in the IL-6 tg cerebellum.
Glutamine synthetase plays a central role in the trafficking of
glutamate, the primary excitatory transmitter in the CNS and
a precursor for the inhibitory transmitter GABA (Mathews and
Diamond, 2003; Albrecht et al., 2010; Tani et al., 2014). Glutamate
that is released at excitatory synapses is taken up by astrocytes,
converted to glutamine by glutamine synthetase and the glu-
tamine is then released to the environment for neuronal uptake
and processing. Glutamine synthetase is an important player in
the neuroprotective role of astrocytes against glutamate toxicity
(Zou et al., 2010; Zhang et al., 2011; Tani et al., 2014). An
increased level of extracellular glutamate, which could lead to glu-
tamate toxicity, induces an upregulation of glutamine synthetase
(Lehmann et al., 2009). Thus, the increased levels of glutamine
synthetase in the IL-6 tg cerebellum may play a protective role
at early ages. Neuronal toxicity is known to occur in the IL-6
transgenic hippocampus and cerebellum, but does not become
prominent until older ages (Heyser et al., 1997).
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The transcription factor C/EBPβ was also elevated in the
cerebellum and not the hippocampus of the IL-6 tg mice and
only at 1–2 month of age. C/EBPβ is expressed prominently
in neurons but also by glial in the CNS (Ejarque-Ortiz et al.,
2007; Kfoury and Kapatos, 2009; Peña-Altamira et al., 2014).
C/EBPβ regulates a host of neuronal genes (Kfoury and Kapatos,
2009) and its upregulation may be a contributing factor to the
lower level of enolase in the IL-6 tg cerebellum at 1–2 months
of age. In addition to enolase, several other neuronal proteins
were reduced in the cerebellum at 1–2 months of age including
Syn 1, GAD 65/67, GluA1 and GluN1, which are all synaptic
proteins. However, the levels of these proteins were reduced at
older ages, whereas the reduced level of enolase and increased
level of C/EBPβ only occurred at 1–2 months of age. Whether
or not the correlation between levels of enolase and C/EBPβ has
a causative aspect will require further study. With respect to the
decreased levels of synaptic proteins in the cerebellum, it seems
unlikely that this decrease reflects neuronal loss, at least at 1–
2 months of age when neuronal death is not prominent in the
IL-6 tg cerebellum. Moreover, at older ages housekeeping and
signal transduction proteins did not show a decrease, as would be
expected if prominent cell loss occurred in the IL-6 tg cerebellum.
One possible explanation is that the decreased levels of synaptic
proteins reflect reduced axon or synapse formation that occurred
during cerebellar development. Our previous studies using a
culture model system showed that the level of α-internexin, a
major neurofilament expressed in axons of cerebellar granule
neurons (Chien et al., 1996), was reduced in granule neuron
cultures exposed to elevated levels of IL-6 during development
(Conroy et al., 2004). α-internexin has been proposed to play
a role in neuronal maturation and axon stability (Chien et al.,
1996) and in the development and organization of postsynaptic
densities (Suzuki et al., 1997). Further studies will be necessary to
determine if the changes in protein levels observed in the current
study correlate with changes in cell structure or cell number.
In the IL-6 tg hippocampus, there were no genotypic dif-
ferences for the levels of β-actin, glutamine synthetase, p42/44
MAPK, and C/EBPβ Based on the high abundance of these pro-
teins in the hippocampus, it seems unlikely that the elevated levels
of IL-6 resulted in prominent cell death, at least at the younger
ages studied. This interpretation is consistent with studies using
fluoro-jade staining for degenerating neurons in 3–4 month old
IL-6 tg and non-tg hippocampus, which revealed no evidence of
cell toxicity (Vallieres et al., 2002). Gross histological analysis of
cresyl violet and TUNEL stained IL-6 tg and non-tg hippocampus
also revealed no evidence of prominent cell loss at 2–6 months of
age (Samland et al., 2003). The levels of Syn 1 and GluN1 were
reduced in the IL-6 tg hippocampus but only at the oldest age
studied (12 months of age). Decreased levels of Syn 1 in the IL-6 tg
hippocampus at 12 months of age was also observed in a previous
study (Heyser et al., 1997). The reduction in Syn 1 and GluN1
at the older age could reflect synaptic damage and/or neuronal
loss, changes that could be important contributors to the deficits
observed in studies of hippocampal-dependent behavior (Heyser
et al., 1997).
In contrast to the IL-6 tg mice, in the CCL2-tg mice there
was little evidence of genotypic differences in the level of cellular
proteins for the hippocampus and no genotypic differences for the
cerebellum. In the CCL2 hippocampus, a modest but significant
increase in the levels of Syn 1 and GluR1 was observed at 3–5
months of age, a genotypic difference that was opposite to the
reduced levels of these proteins observed in the IL-6 hippocampus
at 12 months of age. However, a small but significant decrease
in GAD65/67 was observed in both the CCL2-tg and IL-6 tg
hippocampus, although for different age groups. Thus, IL-6 and
CCL2 appear to directly or indirectly target some of the same
synaptic proteins, effects that could have bearings relative to
conditions where both neuroimmune factors are elevated in the
CNS. There was no evidence of cell loss in the CCL2-tg mice, as
evidenced by the relative lack of genotypic differences.
Taken together, results from our studies show specific profiles
of action of IL-6 and CCL2 in the respective transgenic mice, with
the most pronounced effects occurring in the cerebellum of the
IL-6 tg mice. The pronounced changes in the cerebellum may
be an important factor in the ataxia characteristic of the IL-6 tg
mice. Although CCL2 did not appear to prominently affect the
level of protein expression in the CCL2-tg mice, our previous
studies showed that the persistently elevated levels of CCL2 in
the hippocampus of the CCL2-tg mice produced neuroadaptive
changes that altered aspects of synaptic function and sensitiv-
ity to alcohol (Nelson et al., 2011; Bray et al., 2013). Synaptic
function was also altered in our studies of the hippocampus of
IL-6 tg mice (Nelson et al., 2011), but the effects differed from
that observed in the CCL2-tg mice. Thus, in the CCL2-tg hip-
pocampus, somatic excitability was altered (increased), whereas
in the IL-6 tg hippocampus, the dendritic synaptic response was
altered (increased). The mechanisms mediating these neuroadap-
tive effects on synaptic function remain to be resolved but may
involve some of the changes in protein expression observed in the
current studies.
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